Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | CKS1B | P61024 | 1/20 | 0.41 |
| ▸ | SKP1 | P63208 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23802589 | 0.78 | GPR119 (0.48) | GPR119MAPK1ESR2CKS1BSKP1 | |
| SCHEMBL5183098 | 0.77 | MAPK1 (0.64) | GPR119MAPK1NAMPTESR2 | |
| SCHEMBL29676965 | 0.77 | MAPK1 (0.64) | GPR119MAPK1NAMPTESR2 | |
| SCHEMBL13464773 | 0.77 | KDM4E (0.55) | KDM4EPKMGPR119MAPK1MEN1 | |
| SCHEMBL18878452 | 0.77 | USP2 (0.47) | GPR119MAPK1MEN1KMT2AESR2 | |
| SCHEMBL12828697 | 0.75 | KDM4E (0.43) | KDM4EPKMGPR119MEN1KMT2A | |
| SCHEMBL1374093 | 0.75 | MEN1 (0.68) | KDM4EPKMGPR119MEN1KMT2A | |
| SCHEMBL24621774 | 0.75 | KDM4E (0.53) | KDM4EPKMGPR119MAPK1MEN1 | |
| SCHEMBL12828742 | 0.74 | KDM4E (0.50) | KDM4EPKMGPR119MAPK1MEN1 | |
| SCHEMBL25770784 | 0.74 | KDM4E (0.44) | KDM4EPKMGPR119MAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292305-A1 | Cyclic Ureas | SIRONAX LTD (KY) | 2021-09-23 | — | — | US | disclosed |
| US-20210292305-A1 | Cyclic Ureas | SIRONAX LTD (KY) | 2021-09-23 | — | — | US | disclosed |
| CN-113302183-A | Cyclic ureas | 圣瑞诺有限公司 | 2021-08-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292305-A1 | Cyclic Ureas | RIPK1, RIPK3, RIPK4 | KDM4E 3602/4885PKM 3136/4885GPR119 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.